Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes (NCT07102628)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes: Victorion - RIDES
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.
Who can join: Review the eligibility criteria below.
Location: Novartis Investigative Site — Capital Federal, Buenos Aires
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- Novartis Investigative Site — Capital Federal, Buenos Aires
- Novartis Investigative Site — Garran, Australian Capital Territory
- Novartis Investigative Site — Clayton, Victoria
- Novartis Investigative Site — Edmonton, Alberta
- Novartis Investigative Site — London, Ontario
- Novartis Investigative Site — Newmarket, Ontario
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Québec, Quebec
- Novartis Investigative Site — Beijing, China
- Novartis Investigative Site — Guangzhou, Guangdong
- Novartis Investigative Site — Luoyang, Henan
- Novartis Investigative Site — Xuzhou, Jiangsu
- Novartis Investigative Site — Nanchang, Jiangxi
- Novartis Investigative Site — Wenzhou, Zhejiang
- Novartis Investigative Site — Beijing,
- Novartis Investigative Site — Beijing,
- Novartis Investigative Site — Fuzhou,
- Novartis Investigative Site — Guangzhou,
- Novartis Investigative Site — Guangzhou,
- Novartis Investigative Site — Jining,
- Novartis Investigative Site — Shanghai,
- Novartis Investigative Site — Shanghai,
- Novartis Investigative Site — Tianjin,
- Novartis Investigative Site — Chambray-lès-Tours,
- Novartis Investigative Site — Montpellier,
📞 Contact the Study Coordinator
Phone: +41613241111
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Coronary Syndrome
- LEADERS FREE II: BioFreedom™ Pivotal Study — Huntsville, Alabama
- OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study — Scottsdale, Arizona
- Post Acute Cardiac Event Smoking (PACES) Study — Minneapolis, Minnesota
- DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid — Montreal, Quebec
- Tailoring Post Discharge - Remote Education and Access for Cardiac Health — Winnipeg, Manitoba
- A Prospective Research Investigation of Ischemia Using MCG — Rochester, Minnesota
Explore by condition: All Acute Coronary Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.